Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.
Regeneron loses bid to block Amgen's launch of Eylea biosimilar
Amgen to release biosimilar of Regeneron's Eylea after U.S. appeals court ruling, despite Regeneron's patent infringement claims. Pavblu aims to provide affordable treatment for eye diseases.
How AZ's respiratory wins are ramping up for a bigger prize in COPD
Respiratory drug Fasenra, developed by AstraZeneca, has seen success in treating eosinophilic asthma and EGPA, with ongoing trials for COPD targeting patients with high eosinophil counts. Dr. Donna Carstens highlights the shift from 'treat-to-fail' to 'treat-to-target' in respiratory medicine, emphasizing the importance of precision and guideline-driven approaches.
Lebrikizumab Demonstrates Efficacy in Itch and Skin Clearance Among Patients With AD
Lilly presented phase 3b ADapt study results at the 2024 Fall Clinical Dermatology Conference, showing lebrikizumab's efficacy in improving skin symptoms and quality of life in patients with moderate to severe atopic dermatitis previously treated with dupilumab. The study involved 86 patients, with 83% achieving at least a 4-point improvement in Dermatology Life Quality Index scores by weeks 16 and 24. Safety data indicated mild to moderate adverse events, primarily injection site reactions and mild infections.
Upadacitinib Shows Long-Term Benefits in Teens With Atopic Dermatitis
Upadacitinib (Rinvoq) demonstrated a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, achieving EASI-75 in 84-96% of patients across three phase III trials. Both 15 mg and 30 mg doses met primary endpoints, with acne and nausea as most common adverse events. Long-term outcomes were consistent with known AE profile, with no new signals observed. The analysis involved 542 adolescents, with data gathered from August 2018 to April 2022.
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous ...
Dupixent (dupilumab) significantly reduced itch and urticaria activity scores in biologic-naive CSU patients on antihistamines, with 41% achieving well-controlled disease vs. 23% on placebo. Safety profile consistent with known dermatological indications.
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
Agomab Therapeutics raises $89m in Series D funding, with Sanofi and Invus joining as new investors, to advance clinical trials of AGMB-129, an oral small molecule inhibitor for fibrostenosing Crohn’s disease, with interim results expected in early 2025.
Related Clinical Trials:
Lymph Node-Like Structures May Trigger the Demise of Cancer Tumors
Newly described lymph node-like structures in liver tumors after immunotherapy may be crucial for treating hepatocellular carcinoma, potentially increasing the likelihood of curing the cancer, according to a study by Johns Hopkins researchers.
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
Amgen sets $1,665 list price for biosimilar Eylea, launching Pavblu without legal settlement. GSK invests $800 million in U.S. manufacturing expansion. Roche partners with Dyno Therapeutics for neurological gene therapy. AbbVie and Gideon Richter collaborate on neuropsychiatric treatments. Marinus Pharmaceuticals faces strategic review after Phase 3 seizure drug trial failure.
© Copyright 2024. All Rights Reserved by MedPath